secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ayala Pharmaceuticals, Inc. (—)
CIK:        0001100397
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0000929638-24-001313
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ayala sells AL102/AL101 to Immunome for $20M cash plus 2.18M shares; up to $37.5M milestones
--------------------------------------------------------------------------------

- Closed sale of AL101 and AL102 programs to Immunome for $20M cash, 2,175,489 Immunome shares, and assumed liabilities.
- Up to $37.5M in additional development/commercial milestone payments from Immunome.
- March 1 Convertible Notes ($2M aggregate) converted into 6,666,666 shares of Ayala common stock upon closing.
- Immunome (Nasdaq: IMNM) will advance AL102; Ayala (OTCQX: ADXS) retains potential milestone payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100397/000092963824001313/0000929638-24-001313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100397/000092963824001313/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-24-001313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer